LXR agonists (Anagen Therapeutics)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLXR agonists (Anagen Therapeutics)
Drug Alias NameATI-829
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLiver X receptor agonistsCholesterol modulators
TargetsLiver X receptorCholesterol
Therapy Area/IndicationsLipid Metabolism DisordersAtherosclerosisAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Chicago
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsLipid Metabolism DisordersAtherosclerosisAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A